Abbott Laboratories (BMV:ABT)
Mexico · Delayed Price · Currency is MXN | Market Cap | 2.76T -38.0% |
| Revenue (ttm) | 813.66B +6.6% |
| Net Income | 112.71B -53.5% |
| EPS | 64.36 -53.6% |
| Shares Out | n/a |
| PE Ratio | 24.50 |
| Forward PE | 16.07 |
| Dividend | 44.10 (2.77%) |
| Ex-Dividend Date | Apr 15, 2026 |
| Volume | 64 |
| Open | 1,592.50 |
| Previous Close | 1,650.00 |
| Day's Range | 1,592.50 - 1,592.50 |
| 52-Week Range | 1,413.00 - 2,507.40 |
| Beta | 0.62 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 16, 2026 |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, h... [Read more]
Financial Performance
In 2025, Abbott Laboratories's revenue was $44.33 billion, an increase of 5.67% compared to the previous year's $41.95 billion. Earnings were $6.50 billion, a decrease of -51.49%.
Financial numbers in USD Financial StatementsNews
Tandem Diabetes launches t:slim X2 compatibility with Abbott’s FreeStyle
Tandem Diabetes Care (TNDM) announced that the t:slim X2 insulin pump with Control-IQ+ automated insulin delivery, AID, technology is now compatible with Abbott’s (ABT) FreeStyle Libre 3 Plus continuo...
Abbott initiated with an Outperform at Baird
Baird analyst David Rescott last night initiated coverage of Abbott (ABT) with an Outperform rating and $121 price target The company’s portfolio should deliver “steady” 6%-8% sales and low-double*dig...
3 Dividend Aristocrat Stocks Wall Street Loves Right Now — June 30, 2026
Abbott Laboratories ($ABT), Nucor ($NUE), and Coca-Cola ($KO) are three dividend aristocrat stocks with a Strong Buy rating on Wall Street, according to TipRanks’ Dividend Aristocrat tool. Dividend ar...
Abbott initiated with an Outperform at Baird
Baird analyst David Rescott initiated coverage of Abbott (ABT) with an Outperform rating and $121 price target
Value stocks beat growth when inflation is high. Here are 13 stocks top newsletters are betting on now.
This relationship between inflation and value stocks' outperformance is often overlooked. Many investment experts mistakenly believe that a strong economy, not inflation, is the key to value stocks be...
Prosecutors prepped to charge Abbott, officials opted for settlement, WSJ says
For years, the Justice Department investigated Abbott (ABT) Laboratories’ baby formula facility, where potentially deadly bacteria was found and suspected of causing infant deaths, Dave Michaels, Sadi...
US DOJ closes criminal probe into Abbott over baby formula plant, WSJ reports
The U.S. Justice Department closed a criminal probe into Abbott Laboratories over how it managed a baby formula facility where potentially deadly bacteria were discovered and suspected of cau...
The Baby Formula Probe Produced a Pile of Evidence. Then the DOJ Dropped the Case.
WASHINGTON—The Justice Department spent years investigating Abbott Laboratories ABT 0.94%increase; up pointing triangle over how it managed a baby formula facility where potentially deadly bacteria wa...
3 Dividend Aristocrat Stocks with 20%+ Upside — June 25, 2026
Abbott Laboratories ($ABT), Cintas ($CTAS), and McDonald’s ($MCD) are three dividend aristocrat stocks offering more than 20% upside potential, according to the TipRanks Dividend Aristocrat tool. Divi...
Abbott hosts conference call for second-quarter earnings
ABBOTT PARK, Ill., June 25, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2026 financial results on Thursday, July 16, before the market opens.
Abbott and ALZpath announce license agreement
ALZpath, the leader in blood test-based diagnostic solutions for Alzheimer’s disease, announced a licensing agreement with Abbott (ABT) to incorporate ALZpath’s proprietary phosphorylated Tau 217 anti...
ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease Testing
ALZpath Strengthens Market Leadership with Abbott Agreement to Help Enable Early Alzheimer's Diagnosis at Global Scale CARLSBAD, Calif., June 24, 2026 /PRNewswire/ -- ALZpath Inc., the leader in bloo...
ALZpath signs licensing deal with Abbott to develop Alzheimer's blood test
ALZpath said on Wednesday it had signed a global licensing agreement with Abbott Laboratories to help advance blood-based testing for Alzheimer's disease, as companies race to offer easier-to-use di...
3 Dividend Aristocrat Stocks Wall Street Loves Right Now — June 23, 2026
Abbott Laboratories ($ABT), NextEra Energy ($NEE), and Walmart ($WMT) are the three dividend aristocrat stocks with a Strong Buy rating on Wall Street and payout ratios of more than 70%,…
Missouri appeals court won't send Abbott's appeal of $495 million preterm baby formula verdict to higher court
A Missouri appeals court on Monday declined to send Abbott Laboratories' appeal of a $495 million verdict in a case claiming the company's specialized formula for premature infants caused an Illinoi...
New Similac® survey finds social media pressure to be "perfect" is fueling a shift toward authenticity for the next generation of parents
Despite optimism about parenthood, unrealistic online portrayals are adding pressure for today's young parents Through the new "Love Without Measure" initiative, Similac is standing with parents in pr...
Living Longer Is Big Business. These Stocks Will Benefit.
TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion.
Citi sum-of-the-parts analysis shows Abbott share upside
Citi believes Abbott’s (ABT) parts are worth more than the whole business. Citi’s sum-of-the-parts analysis implies a share price of $99-$104, above the current $89 price, the analyst tells investors…
Abbott declares 410th consecutive quarterly dividend
ABBOTT PARK, Ill., June 12, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share.
Abbott price target lowered to $102 from $120 at BofA
BofA analyst Travis Steed lowered the firm’s price target on Abbott (ABT) to $102 from $120 and keeps a Buy rating on the shares. Noting that the firm’s services team…
New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
Study at ADA's Scientific Sessions shows participants in Abbott's Healthy Food Rx program combined with health coaching had significant health improvements Abbott's Healthy Food Rx program is a Food i...
Abbott announces new data on DKA for people with Type 1, Type 2 diabetes
Abbott (ABT) announced new data revealing diabetic ketoacidosis, DKA, “remains an important, yet often undetected health concern for people living with both Type 1 and Type 2 diabetes,” the company…
New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
Diabetic ketoacidosis (DKA) can develop quickly and is not always easy to detect early Ketone monitoring is not yet routine in diabetes care, which may contribute to missed warning signs of DKA and de...